{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:44:46Z","timestamp":1776858286189,"version":"3.51.2"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["R01MD019094"],"award-info":[{"award-number":["R01MD019094"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40258-026-01036-4","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:36:57Z","timestamp":1774435017000},"page":"459-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review of Microsimulation Models in Cardiometabolic Disease: Model Calibration and Validation"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-4673","authenticated-orcid":false,"given":"Danwei","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8969-3850","authenticated-orcid":false,"given":"Zhixin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6100-4561","authenticated-orcid":false,"given":"Jayoung","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-1250","authenticated-orcid":false,"given":"Jong-Wook","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-8972","authenticated-orcid":false,"given":"David D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"12","key":"1036_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1559-4572.2009.00054.x","volume":"11","author":"EP Kirk","year":"2009","unstructured":"Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens. 2009;11(12):761\u20135.","journal-title":"J Clin Hypertens"},{"key":"1036_CR2","unstructured":"Cardiovascular diseases (CVDs) [Internet]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed 14 Aug 2025."},{"key":"1036_CR3","unstructured":"Diabetes [Internet]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes. Accessed 13 May 2025."},{"key":"1036_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","volume":"32","author":"B Chong","year":"2024","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2024;32:1001\u201315.","journal-title":"Eur J Prev Cardiol"},{"key":"1036_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.19.24315798v1","author":"EOA Wambiya","year":"2024","unstructured":"Wambiya EOA, Gillespie D, Akparibo R, Oguta JO, Akoth C, Otieno P, et al. Application of decision-analytic models to inform integrated care interventions for cardiometabolic multimorbidity: a systematic review [Internet]. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.10.19.24315798v1.","journal-title":"medRxiv"},{"issue":"1","key":"1036_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12913-025-12781-y","volume":"25","author":"S Putri","year":"2025","unstructured":"Putri S, Ciminata G, Lewsey J, Kamaruzaman HFB, Duan Y, Geue C. Policy models for preventative interventions in cardiometabolic diseases: a systematic review. BMC Health Serv Res. 2025;25(1):635.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"1036_CR7","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/S2468-2667(24)00027-6","volume":"9","author":"DD Kim","year":"2024","unstructured":"Kim DD. The role of simulation modelling in public health policy evaluation. Lancet Public Health. 2024;9(3):e150\u20131.","journal-title":"Lancet Public Health."},{"issue":"6","key":"1036_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0272989X05282637","volume":"25","author":"NJ Welton","year":"2005","unstructured":"Welton NJ, Ades AE. Estimation of Markov Chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration. Med Decis Making. 2005;25(6):633\u201345.","journal-title":"Med Decis Making"},{"issue":"52","key":"1036_CR9","first-page":"1","volume":"11","author":"J Karnon","year":"2007","unstructured":"Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, et al. A review and critique of modelling in prioritising and designing screening programmes. Health Technol Assess Winch Engl. 2007;11(52):1\u2013145.","journal-title":"Health Technol Assess Winch Engl."},{"issue":"6","key":"1036_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices Task Force-6. Value Health. 2012;15(6):835\u201342.","journal-title":"Value Health"},{"issue":"1","key":"1036_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/11584600-000000000-00000","volume":"29","author":"T Vanni","year":"2011","unstructured":"Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, et al. Calibrating models in economic evaluation. Pharmacoeconomics. 2011;29(1):35\u201349.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1036_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2165\/00019053-200624110-00002","volume":"24","author":"MC Weinstein","year":"2006","unstructured":"Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24(11):1043\u201353.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1036_CR13","doi-asserted-by":"publisher","first-page":"17208","DOI":"10.1038\/s41598-017-17215-2","volume":"7","author":"D Mori\u00f1a","year":"2017","unstructured":"Mori\u00f1a D, de Sanjos\u00e9 S, Diaz M. Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention. Sci Rep. 2017;7(1):17208.","journal-title":"Sci Rep"},{"issue":"5","key":"1036_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/0272989X221085569","volume":"42","author":"P Shewmaker","year":"2022","unstructured":"Shewmaker P, Chrysanthopoulou SA, Iskandar R, Lake D, Jutkowitz E. Microsimulation model calibration with approximate Bayesian computation in R: a tutorial. Med Decis Mak. 2022;42(5):557\u201370.","journal-title":"Med Decis Mak"},{"issue":"6","key":"1036_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","volume":"15","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Value Health. 2012;15(6):843\u201350.","journal-title":"Value Health"},{"key":"1036_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1036_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/11584610-000000000-00000","volume":"29","author":"J Karnon","year":"2011","unstructured":"Karnon J, Vanni T. Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria. Pharmacoeconomics. 2011;29(1):51\u201362.","journal-title":"Pharmacoeconomics"},{"key":"1036_CR18","doi-asserted-by":"crossref","unstructured":"Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. In: NIHR Health Technology Assessment programme: Executive Summaries [Internet]. NIHR Journals Library; 2004. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK62255\/. Accessed 17 Feb 2026.","DOI":"10.3310\/hta8360"},{"issue":"11","key":"1036_CR19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40273-019-00837-x","volume":"37","author":"F Alarid-Escudero","year":"2019","unstructured":"Alarid-Escudero F, Krijkamp EM, Pechlivanoglou P, Jalal H, Kao SYZ, Yang A, et al. A need for change! a coding framework for improving transparency in decision modeling. Pharmacoeconomics. 2019;37(11):1329\u201339.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1036_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/1471-2458-6-213","volume":"18","author":"B Unal","year":"2006","unstructured":"Unal B, Capewell S, Critchley JA. Coronary heart disease policy models: a systematic review. BMC Public Health. 2006;18(6):213.","journal-title":"BMC Public Health"},{"issue":"2","key":"1036_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40258-013-0012-6","volume":"11","author":"H Haji Ali Afzali","year":"2013","unstructured":"Haji Ali Afzali H, Gray J, Karnon J. Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases: a review and suggested reporting framework. Appl Health Econ Health Policy. 2013;11(2):85\u201393.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"1036_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40273-023-01312-4","volume":"42","author":"M Antoniou","year":"2024","unstructured":"Antoniou M, Mateus C, Hollingsworth B, Titman A. A systematic review of methodologies used in models of the treatment of diabetes mellitus. Pharmacoeconomics. 2024;42(1):19\u201340.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1036_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-051812","volume":"11","author":"L Osipenko","year":"2021","unstructured":"Osipenko L. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019. BMJ Open. 2021;11(10):e051812.","journal-title":"BMJ Open"},{"key":"1036_CR24","doi-asserted-by":"publisher","unstructured":"Jaime Caro J, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a Report of the ISPOR-SMDM modeling good research practices task force\u20131. 2012. https:\/\/doi.org\/10.1177\/0272989X12454577","DOI":"10.1177\/0272989X12454577"},{"issue":"15","key":"1036_CR25","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1177\/2047487316651982","volume":"23","author":"MC Penaloza-Ramos","year":"2016","unstructured":"Penaloza-Ramos MC, Jowett S, Barton P, Roalfe A, Fletcher K, Taylor CJ, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. Eur J Prev Cardiol. 2016;23(15):1590\u20138.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"1036_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/0272989X16636851","volume":"36","author":"A van der Steen","year":"2016","unstructured":"van der Steen A, van Rosmalen J, Kroep S, van Hees F, Steyerberg EW, de Koning HJ, et al. Calibrating parameters for microsimulation disease models: a review and comparison of different goodness-of-fit criteria. Med Decis Mak Int J Soc Med Decis Mak. 2016;36(5):652\u201365.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak."},{"key":"1036_CR27","unstructured":"Schunn CD, Wallach D. Evaluating goodness-of-fit in comparison of models to data."},{"issue":"7","key":"1036_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/11314830-000000000-00000","volume":"27","author":"NK Stout","year":"2009","unstructured":"Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27(7):533\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1036_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007893","volume":"16","author":"CM Hazelbag","year":"2020","unstructured":"Hazelbag CM, Dushoff J, Dominic EM, Mthombothi ZE, Delva W. Calibration of individual-based models to epidemiological data: a systematic review. PLoS Comput Biol. 2020;16(5):e1007893.","journal-title":"PLoS Comput Biol"},{"key":"1036_CR30","volume-title":"Theory of point estimation","author":"EL Lehmann","year":"2006","unstructured":"Lehmann EL, Casella G. Theory of point estimation. Berlin: Springer Science & Business Media; 2006."},{"key":"1036_CR31","doi-asserted-by":"publisher","unstructured":"Statistical inference for stochastic simulation models\u2014theory and application. https:\/\/doi.org\/10.1111\/j.1461-0248.2011.01640.x.","DOI":"10.1111\/j.1461-0248.2011.01640.x"},{"issue":"5","key":"1036_CR32","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/schbul\/sbad175","volume":"50","author":"C De Oliveira","year":"2024","unstructured":"De Oliveira C, Mason J, Luu L, Iwajomo T, Simbulan F, Kurdyak P, et al. The PSY-SIM model: using real-world data to inform health care policy for individuals with chronic psychotic disorders. Schizophr Bull. 2024;50(5):1094\u2013103.","journal-title":"Schizophr Bull"},{"issue":"8","key":"1036_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jval.2023.03.006","volume":"26","author":"S Pryor","year":"2023","unstructured":"Pryor S, Savoye M, Nowicka P, Price G, Sharifi M, Yaesoubi R. Cost-effectiveness and long-term savings of the Bright Bodies intervention for childhood obesity. Value Health. 2023;26(8):1183\u201391.","journal-title":"Value Health"},{"issue":"740","key":"1036_CR34","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.3399\/BJGP.2023.0198","volume":"74","author":"R Wu","year":"2024","unstructured":"Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, et al. Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model. Br J Gen Pract. 2024;74(740):e189\u201398.","journal-title":"Br J Gen Pract"},{"issue":"12","key":"1036_CR35","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1136\/gutjnl-2023-330437","volume":"72","author":"M Saumoy","year":"2023","unstructured":"Saumoy M, Gandhi D, Buller S, Patel S, Schneider Y, Cote G, et al. Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses. Gut. 2023;72(12):2250\u20139.","journal-title":"Gut"},{"issue":"9","key":"1036_CR36","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jval.2023.05.013","volume":"26","author":"TJ Hoerger","year":"2023","unstructured":"Hoerger TJ, Hilscher R, Neuwahl S, Kaufmann MB, Shao H, Laxy M, et al. A new Type 2 diabetes microsimulation model to estimate long-term health outcomes, costs, and cost-effectiveness. Value Health. 2023;26(9):1372\u201380.","journal-title":"Value Health"},{"issue":"1","key":"1036_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11524-022-00699-3","volume":"100","author":"Z Lou","year":"2023","unstructured":"Lou Z, Yi SS, Pomeranz J, Suss R, Russo R, Rummo PE, et al. The health and economic impact of using a sugar sweetened beverage tax to fund fruit and vegetable subsidies in New York City: a modeling study. J Urban Health. 2023;100(1):51\u201362.","journal-title":"J Urban Health"},{"key":"1036_CR38","doi-asserted-by":"crossref","unstructured":"Li C, Chen K, Cornelius V, Tomeny E, Wang Y, Yang X, et al. Applicability and cost-effectiveness of the systolic blood pressure intervention trial (SPRINT) in the Chinese population: a cost-effectiveness modeling study. PLoS Med. 2021;18(3):e1003515.","DOI":"10.1371\/journal.pmed.1003515"},{"issue":"5","key":"1036_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5694\/mja2.51860","volume":"218","author":"P Venkataraman","year":"2023","unstructured":"Venkataraman P, Neil AL, Mitchell GK, Stanton T, Nicholls S, Tonkin AM, et al. The cost-effectiveness of coronary calcium score-guided statin therapy initiation for Australians with family histories of premature coronary artery disease. Med J Aust. 2023;218(5):216\u201322.","journal-title":"Med J Aust"},{"key":"1036_CR40","doi-asserted-by":"crossref","unstructured":"Wang M, Liu J, Bellows BK, Qi Y, Sun J, Liu J, et al. Impact of China\u2019s low centralized medicine procurement prices on the cost-effectiveness of statins for the primary prevention of atherosclerotic cardiovascular disease. Glob Heart. 2020;15(1):43.","DOI":"10.5334\/gh.830"},{"issue":"5","key":"1036_CR41","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40258-019-00494-3","volume":"17","author":"RF Pollock","year":"2019","unstructured":"Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hall\u00e9n N, et al. Long-term cost-effectiveness of Insulin Degludec versus insulin glargine U100 in the UK: evidence from the Basal-bolus subgroup of the DEVOTE trial (DEVOTE 16). Appl Health Econ Health Policy. 2019;17(5):615\u201327.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"1036_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48312-z","volume":"9","author":"A Khademi","year":"2019","unstructured":"Khademi A, Shi L, Nasrollahzadeh AA, Narayanan H, Chen L. Comparing the lifestyle interventions for prediabetes: an integrated microsimulation and population simulation model. Sci Rep. 2019;9(1):11927.","journal-title":"Sci Rep"},{"issue":"1","key":"1036_CR43","first-page":"31","volume":"34","author":"Y Arbel","year":"2018","unstructured":"Arbel Y, Bennell MC, Goodman SG, Wijeysundera HC. Cost-effectiveness of different durations of dual-antiplatelet use after percutaneous coronary intervention. Can J Cardiol. 2018;34(1):31\u20137.","journal-title":"Can J Cardiol"},{"key":"1036_CR44","doi-asserted-by":"crossref","unstructured":"Mytton OT, Jackson C, Steinacher A, Goodman A, Langenberg C, Griffin S, et al. The current and potential health benefits of the National Health Service Health Check cardiovascular disease prevention programme in England: a microsimulation study. PLoS Med. 2018;15(3):e1002517.","DOI":"10.1371\/journal.pmed.1002517"},{"issue":"8","key":"1036_CR45","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/dme.13349","volume":"34","author":"PR Breeze","year":"2017","unstructured":"Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle P, et al. Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK. Diabet Med. 2017;34(8):1136\u201344.","journal-title":"Diabet Med"},{"key":"1036_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ijcard.2015.10.171","volume":"203","author":"BJH Van Kempen","year":"2016","unstructured":"Van Kempen BJH, Ferket BS, Steyerberg EW, Max W, Hunink MMG, Fleischmann KE. Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population. Int J Cardiol. 2016;203:422\u201331.","journal-title":"Int J Cardiol"},{"issue":"9","key":"1036_CR47","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.115.019985","volume":"133","author":"S Basu","year":"2016","unstructured":"Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target-versus risk-based blood pressure treatment. Circulation. 2016;133(9):840\u20138.","journal-title":"Circulation"},{"issue":"4","key":"1036_CR48","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jval.2024.01.010","volume":"27","author":"K Szafranski","year":"2024","unstructured":"Szafranski K, De Pouvourville G, Greenberg D, Harris S, Jendle J, Shaw JE, et al. The determination of diabetes utilities, costs, and effects model: a cost-utility tool using patient-level microsimulation to evaluate sensor-based glucose monitoring systems in type 1 and type 2 diabetes: comparative validation. Value Health. 2024;27(4):500\u20137.","journal-title":"Value Health."},{"key":"1036_CR49","doi-asserted-by":"crossref","unstructured":"Burke JF, Copeland LL, Sussman JB, Hayward RA, Gross AL, Brice\u00f1o EM, et al. Development and validation of the Michigan Chronic Disease Simulation Model (MICROSIM). PLoS One. 2024;19(5):0300005.","DOI":"10.1371\/journal.pone.0300005"},{"issue":"4","key":"1036_CR50","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S2468-2667(24)00028-8","volume":"9","author":"A Head","year":"2024","unstructured":"Head A, Birkett M, Fleming K, Kypridemos C, O\u2019Flaherty M. Socioeconomic inequalities in accumulation of multimorbidity in England from 2019 to 2049: a microsimulation projection study. Lancet Public Health. 2024;9(4):e231\u20139.","journal-title":"Lancet Public Health."},{"issue":"7\u20138","key":"1036_CR51","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/0272989X231196916","volume":"43","author":"DD Kim","year":"2023","unstructured":"Kim DD, Wang L, Lauren BN, Liu J, Marklund M, Lee Y, et al. Development and validation of the US diabetes, obesity, cardiovascular disease microsimulation (DOC-M) model: health disparity and economic impact model. Med Decis Mak. 2023;43(7\u20138):930\u201348.","journal-title":"Med Decis Mak"},{"key":"1036_CR52","doi-asserted-by":"crossref","unstructured":"Scarborough P, Kaur A, Cobiac LJ. Forecast of myocardial infarction incidence, events and prevalence in England to 2035 using a microsimulation model with endogenous disease outcomes. PLoS One. 2022;17(6):e0270189.","DOI":"10.1371\/journal.pone.0270189"},{"key":"1036_CR53","doi-asserted-by":"crossref","unstructured":"Ward ZJ, Willett WC, Hu FB, Pacheco LS, Long MW, Gortmaker SL. Excess mortality associated with elevated body weight in the USA by state and demographic subgroup: A modelling study. eClinicalMedicine [Internet]. 2022;48 ((Ward Z.J., zward@hsph.harvard.edu) Center for Health Decision Science, Harvard T.H. Chan School of Public Health, 718 Huntington Ave, Boston, MA, United States). https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L2017892106&from=export","DOI":"10.1016\/j.eclinm.2022.101429"},{"issue":"4","key":"1036_CR54","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/dc21-1607","volume":"45","author":"BS Ferket","year":"2022","unstructured":"Ferket BS, Hunink MGM, Masharani U, Max W, Yeboah J, Burke GL, et al. Lifetime cardiovascular disease risk by coronary artery calcium score in individuals with and without diabetes: an analysis from the multi-ethnic study of atherosclerosis. Diabetes Care. 2022;45(4):975\u201382.","journal-title":"Diabetes Care"},{"issue":"11","key":"1036_CR55","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1007\/s13300-020-00923-w","volume":"11","author":"M Willis","year":"2020","unstructured":"Willis M, Asseburg C, Slee A, Nilsson A, Neslusan C. Development and internal validation of a discrete event simulation model of diabetic kidney disease using CREDENCE trial data. Diabetes Ther. 2020;11(11):2657\u201376.","journal-title":"Diabetes Ther."},{"issue":"6","key":"1036_CR56","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1089\/dia.2018.0393","volume":"21","author":"P Kazemian","year":"2019","unstructured":"Kazemian P, Wexler DJ, Fields NF, Parker RA, Zheng A, Walensky RP. Development and validation of PREDICT-DM: a new microsimulation model to project and evaluate complications and treatments of type 2 diabetes mellitus. Diabetes Technol Ther. 2019;21(6):344\u201355.","journal-title":"Diabetes Technol Ther"},{"issue":"S1","key":"1036_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/hec.3986","volume":"30","author":"M Kasajima","year":"2021","unstructured":"Kasajima M, Hashimoto H, Suen SC, Chen B, Jalal H, Eggleston K, et al. Future projection of the health and functional status of older people in Japan: a multistate transition microsimulation model with repeated cross-sectional data. Health Econ UK. 2021;30(S1):30\u201351.","journal-title":"Health Econ UK"},{"issue":"9","key":"1036_CR58","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40273-018-0662-1","volume":"36","author":"H Shao","year":"2018","unstructured":"Shao H, Fonseca V, Stoecker C, Liu S, Shi L. Novel risk engine for diabetes progression and mortality in USA: building, relating, assessing, and validating outcomes (BRAVO). Pharmacoeconomics. 2018;36(9):1125\u201334.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1036_CR59","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41366-018-0210-2","volume":"43","author":"T Lung","year":"2019","unstructured":"Lung T, Jan S, Tan EJ, Killedar A, Hayes A. Impact of overweight, obesity and severe obesity on life expectancy of Australian adults. Int J Obes. 2019;43(4):782\u20139.","journal-title":"Int J Obes"},{"issue":"6","key":"1036_CR60","first-page":"20","volume":"28","author":"D Hennessy","year":"2017","unstructured":"Hennessy D, Garner R, Flanagan WM, Wall R, Nadeau C. Development of a population-based microsimulation model of body mass index. Health Rep. 2017;28(6):20\u201330.","journal-title":"Health Rep"},{"issue":"7","key":"1036_CR61","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0272989X17706081","volume":"37","author":"A Pandya","year":"2017","unstructured":"Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA. Validation of a cardiovascular disease policy microsimulation model using both survival and receiver operating characteristic curves. Med Decis Making. 2017;37(7):802\u201314.","journal-title":"Med Decis Making"},{"issue":"23","key":"1036_CR62","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1136\/heartjnl-2016-310970","volume":"103","author":"I Schlackow","year":"2017","unstructured":"Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, et al. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart. 2017;103(23):1880\u201390.","journal-title":"Heart"},{"issue":"2","key":"1036_CR63","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0272989X13518272","volume":"35","author":"JD Goldhaber-Fiebert","year":"2015","unstructured":"Goldhaber-Fiebert JD, Brandeau ML. Modeling and calibration for exposure to time-varying, modifiable risk factors: the example of smoking behavior in India. Med Decis Mak. 2015;35(2):196\u2013210.","journal-title":"Med Decis Mak"},{"issue":"1","key":"1036_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"issue":"11","key":"1036_CR65","doi-asserted-by":"publisher","first-page":"851","DOI":"10.7326\/M19-2797","volume":"171","author":"DD Kim","year":"2019","unstructured":"Kim DD, Neumann PJ. Comparative modeling to inform health policy decisions: a step forward. Ann Intern Med. 2019;171(11):851\u20132.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1036_CR66","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1177\/0272989X18806497","volume":"38","author":"M Buskermolen","year":"2018","unstructured":"Buskermolen M, Gini A, Naber SK, Toes-Zoutendijk E, de Koning HJ, Lansdorp-Vogelaar I. Modeling in colorectal cancer screening: assessing external and predictive validity of MISCAN-Colon microsimulation model using NORCCAP trial results. Med Decis Mak. 2018;38(8):917\u201329.","journal-title":"Med Decis Mak"},{"issue":"11","key":"1036_CR67","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s40273-019-00825-1","volume":"37","author":"S Kent","year":"2019","unstructured":"Kent S, Becker F, Feenstra T, Tran-Duy A, Schlackow I, Tew M, et al. The challenge of transparency and validation in health economic decision modelling: a view from mount hood. Pharmacoeconomics. 2019;37(11):1305\u201312.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1036_CR68","doi-asserted-by":"publisher","first-page":"432","DOI":"10.7326\/M17-1153","volume":"167","author":"JT Cohen","year":"2017","unstructured":"Cohen JT, Neumann PJ, Wong JB. A call for open-source cost-effectiveness analysis. Ann Intern Med. 2017;167(6):432\u20133.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1036_CR69","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000813","volume":"55","author":"WV Padula","year":"2017","unstructured":"Padula WV, McQueen RB, Pronovost PJ. Finding resolution for the responsible transparency of economic models in health and medicine. Med Care. 2017;55(11):915.","journal-title":"Med Care"},{"issue":"1","key":"1036_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40273-016-0479-8","volume":"35","author":"WCN Dunlop","year":"2017","unstructured":"Dunlop WCN, Mason N, Kenworthy J, Akehurst RL. Benefits, challenges and potential strategies of open source health economic models. Pharmacoeconomics. 2017;35(1):125\u20138.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1036_CR71","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13643-018-0786-6","volume":"7","author":"L Neimann Rasmussen","year":"2018","unstructured":"Neimann Rasmussen L, Montgomery P. The prevalence of and factors associated with inclusion of non-English language studies in Campbell systematic reviews: a survey and meta-epidemiological study. Syst Rev. 2018;7(1):129.","journal-title":"Syst Rev"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01036-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01036-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01036-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:04:22Z","timestamp":1776855862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-026-01036-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01036-4","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Danwei Yang: No disclosures. Zhixin Cao: No disclosures. Jayoung Byun: No disclosures. Jong-Wook Ban: No disclosures. David D. Kim: No disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Extraction forms and the final extraction dataset are available at online Supplementary Material.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The analysis code used to generate the results and figures is publicly available at\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}